Summary
This prediction ended on 09.12.23 with a price of €7.40. The price for Altimmune massively increased, which is bad news for the SELL prediction by dimontalban. dimontalban has 70% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Altimmune | 1.657% | 1.657% |
| iShares Core DAX® | 0.383% | -1.593% |
| iShares Nasdaq 100 | 1.543% | 7.530% |
| iShares Nikkei 225® | 2.596% | 4.525% |
| iShares S&P 500 | 0.573% | 4.229% |
According to dimontalban what are the pros and cons of Altimmune for the foreseeable future?
Pros
Capable Management
Good culture
Sustainability is very important
Future proof or reliable business model
Cons
overvalued
negative Cash Flow expected
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Decining EBIT margin than peer group
Very low/no dividend yield expected
Little Investments for future growth
Junk rating
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Little innovation
No uniques
Dependend from few customers or products
Growths slower than the competition
high free float
Higher risks for its business
Below average Marketposition
Very high cyclical dependencies
Little known brand
Comments by dimontalban for this prediction
In the thread Altimmune diskutieren
Sell mit Kursziel 1,0